Deerfield Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $147M | Sell |
1,167,802
-321,198
| -22% | -$40.4M | 2.66% | 10 |
|
|
2025
Q1 | $165M | Buy |
1,489,000
+627,000
| +73% | +$69.3M | 3.25% | 4 |
|
|
2024
Q4 | $118M | Sell |
862,000
-454,590
| -35% | -$62.1M | 2.23% | 10 |
|
|
2024
Q3 | $152M | Buy |
1,316,590
+625,586
| +91% | +$72.1M | 2.27% | 8 |
|
|
2024
Q2 | $95.1M | Hold |
691,004
| – | – | 1.58% | 19 |
|
|
2024
Q1 | $95.3M | Sell |
691,004
-205,715
| -23% | -$28.4M | 1.66% | 20 |
|
|
2023
Q4 | $118M | Sell |
896,719
-312,995
| -26% | -$41.2M | 2.18% | 10 |
|
|
2023
Q3 | $136M | Hold |
1,209,714
| – | – | 3% | 7 |
|
|
2023
Q2 | $114M | Sell |
1,209,714
-535,000
| -31% | -$50.5M | 2.44% | 10 |
|
|
2023
Q1 | $177M | Buy |
1,744,714
+232,000
| +15% | +$23.5M | 3.94% | 3 |
|
|
2022
Q4 | $181M | Hold |
1,512,714
| – | – | 3.74% | 4 |
|
|
2022
Q3 | $161M | Sell |
1,512,714
-500,000
| -25% | -$53.1M | 3.2% | 5 |
|
|
2022
Q2 | $196M | Buy |
2,012,714
+354,914
| +21% | +$34.6M | 4.05% | 5 |
|
|
2022
Q1 | $155M | Buy |
1,657,800
+279,855
| +20% | +$26.2M | 3.47% | 6 |
|
|
2021
Q4 | $117M | Buy |
1,377,945
+235,530
| +21% | +$20.1M | 2.46% | 8 |
|
|
2021
Q3 | $110M | Buy |
1,142,415
+417,415
| +58% | +$40M | 2.14% | 10 |
|
|
2021
Q2 | $70.6M | Hold |
725,000
| – | – | 1.25% | 19 |
|
|
2021
Q1 | $70.5M | Buy |
+725,000
| New | +$70.5M | 1.48% | 17 |
|
|
2014
Q3 | – | Sell |
-53,094
| Closed | -$788K | – | 130 |
|
|
2014
Q2 | $788K | Sell |
53,094
-24,900
| -32% | -$370K | 0.03% | 103 |
|
|
2014
Q1 | $1.26M | Buy |
+77,994
| New | +$1.26M | 0.05% | 107 |
|